An 8 Week Prospective, Multicenter, Randomized, Double-Blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ Versus Amlodipine in African American Patients With Stage 2 Hypertension.

Trial Profile

An 8 Week Prospective, Multicenter, Randomized, Double-Blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ Versus Amlodipine in African American Patients With Stage 2 Hypertension.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 May 2011

At a glance

  • Drugs Aliskiren/hydrochlorothiazide; Amlodipine
  • Indications Hypertension
  • Focus Biomarker; Therapeutic Use
  • Acronyms ATLAAST
  • Sponsors Novartis
  • Most Recent Events

    • 14 Mar 2010 Results presented at the 59th Annual Scientific Session of the American College of Cardiology (ACC 2010).
    • 22 Jul 2009 Actual patient number (332) added as reported by ClinicalTrials.gov.
    • 22 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top